Advancing Pipelines, Liquidity Growth, Cost-reduction Initiatives and Breakthrough Studies - Research Report on Alkermes, Abiomed, Gentium, Amarin, and VIVUS
Editor Note: For more information about this release, please scroll to bottom
NEW YORK, November 6, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Alkermes plc (NASDAQ: ALKS), Abiomed Inc. (NASDAQ: ABMD), Gentium S.p.A (NASDAQ: GENT), Amarin Corporation plc (NASDAQ: AMRN), and VIVUS Inc. (NASDAQ: VVUS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Alkermes plc Research Report
On October 31, 2013, Alkermes plc (Alkermes) reported its financial results for the quarter ended September 30, 2013 (This is the second quarter of the nine-month period ending December 31, 2013, as the Company transitions to reporting on a calendar year basis). Alkermes reported total revenues of $139.8 million, compared to $124.0 million in Q2 FY 2012. GAAP net loss for the quarter was $7.8 million, or a basic and diluted GAAP loss per share of $0.06, compared to GAAP net loss of $16.7 million, or a basic and diluted GAAP loss per share of $0.13, in Q2 FY 2012. "This quarter's financial results demonstrate the power of our business model to generate substantial cash flows while also providing the resources to invest in our advancing pipeline," commented James Frates, Chief Financial Officer of Alkermes. "Our commercial portfolio demonstrated another strong quarter with 38% year-over-year revenue growth from our key products." The Full Research Report on Alkermes plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/e2f3_ALKS]
--
Abiomed Inc. Research Report
On October 16, 2013, Abiomed Inc. (Abiomed) announced the Company's earnings release and conference call schedule. The Company will report its Q2 FY 2014 financial results on November 6, 2013, Wednesday. Following the earnings release, Abiomed will host a conference call to discuss the results at 8:00 a.m. ET, on the same day. The Full Research Report on Abiomed Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/ea34_ABMD]
--
Gentium S.p.A Research Report
On October 31, 2013, Gentium S.p.A. (Gentium) reported its Q3 2013 financial results with total revenues of €11.8 million compared to €7.4 million in Q3 2012. Net income for the quarter was €2.7 million compared to €0.3 million in Q3 2012. Diluted net income per share totaled €0.164 compared to €0.016 in Q3 2012. Dr. Khalid Islam, Chairman and CEO of Gentium, commented, "We are proud that Gentium has achieved a major milestone in obtaining the Marketing Authorization for Defitelio® (defibrotide) for treatment of severe hepatic veno-occlusive disease ("sVOD"). As the first drug to be approved for the treatment of sVOD, Defitelio® (defibrotide) will provide physician with a life-saving option addressing a high unmet medical need for a disease with a high mortality rate, in excess of 80%." The Full Research Report on Gentium S.p.A - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/e100_GENT]
--
Amarin Corporation plc Research Report
On October 22, 2013, Amarin Corporation plc (Amarin) announced its plans to reduce the Company's operating expenses through eliminating 50% of its staff positions worldwide, following the recent recommendation of the US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee against the potential Vascepa® (icosapent ethyl) label expansion. The Company reported that it will retain approximately half of its highest performing sales professionals in targeted geographical areas and pursue continued prescription growth of Vascepa in the current approved indication. Amarin informed that it expects its cash burn for 2014 to be below $80 million. The Full Research Report on Amarin Corporation plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/7cf9_AMRN]
--
VIVUS Inc. Research Report
On October 31, 2013, VIVUS Inc. (Vivus) announced that a newly-published study showed Qsymia capsules CIV produced significantly greater weight loss, and at lower doses, compared to phentermine or topiramate administered as monotherapies in obese adults. In this study, the effect of Qsymia on heart rate was similar to placebo. Qsymia was designed to allow once-daily dosing, with phentermine immediate-release (IR) released in the morning and topiramate extended-release (ER) released in the evening. The study notes that this unique pharmacokinetic profile may be responsible for the improved efficacy and tolerability of the combination doses versus their monotherapy counterparts. The Full Research Report on VIVUS Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/8ae9_VVUS]
----
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article